BR0111264A - Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização - Google Patents

Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização

Info

Publication number
BR0111264A
BR0111264A BR0111264-3A BR0111264A BR0111264A BR 0111264 A BR0111264 A BR 0111264A BR 0111264 A BR0111264 A BR 0111264A BR 0111264 A BR0111264 A BR 0111264A
Authority
BR
Brazil
Prior art keywords
factor viia
compounds
formula
derivatives
preparation
Prior art date
Application number
BR0111264-3A
Other languages
English (en)
Inventor
Otmar Klingler
Manfred Schudok
Hans-Peter Nestler
Hans Matter
Herman Schreuder
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0111264A publication Critical patent/BR0111264A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS (TIO)URéIA INIBIDORES DO FATOR VIIa, SUA PREPARAçãO E SUA UTILIZAçãO". A presente invenção refere-se a compostos de fórmula I em que R^ 1^, R^ 2^, R^ 3^, R^ 4^, R^ 5^, R^ 6^, A, X, m e n têm os significados indicados nas reivindicações. Os compostos de fórmula 1 são valiosos compostos farmacologicamente ativos. Eles apresentam um forte efeito antitrombático e são adequados, por exemplo, para a terapia e profilaxia de doenças tromboembólicas e restenoses. Eles são unibidores reversíveis do fator VIIa da enzima de coagulação sang³ínea e podem, geralmente, ser aplicados em condições, nas quais uma atividade indesejada do fator VIIa esteja presente, ou para a cura ou prevenção da qual se pretenda uma inibição do fator VIIa. A invenção, além disso, refere-se a processos para preparação dos compostos de fórmula I, seu uso, em particular como ingredientes ativos em produtos farmacêuticos e preparações farmacêuticas que os contém.
BR0111264-3A 2000-06-06 2001-05-26 Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização BR0111264A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00112116A EP1162194A1 (en) 2000-06-06 2000-06-06 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
PCT/EP2001/006029 WO2001094301A2 (en) 2000-06-06 2001-05-26 Factor viia inhibitory (thio)urea derivatives, their preparation and their use

Publications (1)

Publication Number Publication Date
BR0111264A true BR0111264A (pt) 2003-06-17

Family

ID=8168926

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111264-3A BR0111264A (pt) 2000-06-06 2001-05-26 Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização

Country Status (30)

Country Link
US (1) US6743790B2 (pt)
EP (2) EP1162194A1 (pt)
JP (1) JP4809570B2 (pt)
KR (1) KR101011345B1 (pt)
CN (1) CN1208314C (pt)
AR (1) AR030936A1 (pt)
AU (2) AU2001277494B2 (pt)
BR (1) BR0111264A (pt)
CA (1) CA2410862C (pt)
CZ (1) CZ20023963A3 (pt)
DE (1) DE60139320D1 (pt)
DK (1) DK1299354T3 (pt)
EE (1) EE200200617A (pt)
ES (1) ES2330412T3 (pt)
HK (1) HK1055941A1 (pt)
HR (1) HRP20020961A2 (pt)
HU (1) HUP0301631A2 (pt)
IL (2) IL153220A0 (pt)
MX (1) MXPA02009789A (pt)
MY (1) MY129363A (pt)
NO (1) NO328546B1 (pt)
NZ (1) NZ522960A (pt)
PL (1) PL359584A1 (pt)
PT (1) PT1299354E (pt)
RU (1) RU2286337C2 (pt)
SK (1) SK17032002A3 (pt)
TW (1) TWI283662B (pt)
WO (1) WO2001094301A2 (pt)
YU (1) YU89202A (pt)
ZA (1) ZA200209018B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183277B2 (en) 2002-04-27 2007-02-27 Merck Patent Gmbh Carboxylic acid amides
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
US7273886B2 (en) * 2003-05-20 2007-09-25 Genentech, Inc. Benzofuran inhibitors of factor VIIa
EP1628954A2 (en) * 2003-05-20 2006-03-01 Genentech, Inc. Acylsulfamide inhibitors of factor viia
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7459472B2 (en) * 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
EP1810965A4 (en) * 2004-10-13 2009-10-28 Eisai R&D Man Co Ltd HYDRAZIDE DERIVATIVES
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1856037A1 (en) * 2005-02-24 2007-11-21 Novo Nordisk Health Care AG Amidino-compounds for stabilizing factor vii polypeptide formulations
JP2008531525A (ja) * 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド製剤を安定化する化合物
WO2006089953A1 (en) * 2005-02-24 2006-08-31 Novo Nordisk Health Care Ag Compounds for stabilizing factor vii polypeptide formulations
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
PT2000465E (pt) 2006-03-24 2011-02-10 Eisai R&D Man Co Ltd Derivado de triazolona
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009038157A1 (ja) * 2007-09-21 2009-03-26 Eisai R & D Management Co., Ltd. ２，３－ジヒドロ－イミノイソインドール誘導体
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CN106518742B (zh) 2011-10-26 2020-01-21 阿勒根公司 作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
SG11201406629VA (en) * 2012-04-16 2014-11-27 Allergan Inc (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CN104717973A (zh) * 2012-10-10 2015-06-17 诺和诺德保健Ag（股份有限公司） 因子vii多肽的液体药物组合物
JP6196328B2 (ja) 2013-03-06 2017-09-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚疾患を治療するためのホルミルペプチド受容体２アゴニストの使用
JP6196327B2 (ja) 2013-03-06 2017-09-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
EP0570507A4 (en) * 1991-02-05 1994-09-21 Smithkline Beecham Corp Anti-aggregatory peptides containing an aromatic ester or amide
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
JP3387948B2 (ja) * 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) * 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313269D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Allophanic acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists
CA2174516A1 (en) * 1993-10-19 1995-04-27 Yoshiharu Ikeda 2,3-diaminopropionic acid derivative
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
CA2243507A1 (en) * 1996-01-30 1997-08-07 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
BR9814645A (pt) * 1997-11-18 2001-07-31 Teijin Ltd Derivados de amina cìclica e seu uso como medicamentos
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
MXPA02009789A (es) 2003-03-12
AU2001277494B2 (en) 2006-05-04
AR030936A1 (es) 2003-09-03
SK17032002A3 (sk) 2003-05-02
PT1299354E (pt) 2009-10-01
EE200200617A (et) 2004-04-15
JP2003535844A (ja) 2003-12-02
AU7749401A (en) 2001-12-17
HRP20020961A2 (en) 2004-12-31
CA2410862C (en) 2009-11-10
CA2410862A1 (en) 2001-12-13
WO2001094301A3 (en) 2002-04-04
DK1299354T3 (da) 2009-11-16
KR20030007911A (ko) 2003-01-23
ZA200209018B (en) 2003-10-08
MY129363A (en) 2007-03-30
US20020052417A1 (en) 2002-05-02
US6743790B2 (en) 2004-06-01
NO20025810D0 (no) 2002-12-03
CN1208314C (zh) 2005-06-29
YU89202A (sh) 2006-05-25
EP1299354A2 (en) 2003-04-09
HUP0301631A2 (hu) 2003-09-29
NO20025810L (no) 2002-12-03
IL153220A (en) 2008-11-03
RU2286337C2 (ru) 2006-10-27
HK1055941A1 (en) 2004-01-30
KR101011345B1 (ko) 2011-01-28
IL153220A0 (en) 2003-07-06
EP1162194A1 (en) 2001-12-12
WO2001094301A2 (en) 2001-12-13
PL359584A1 (en) 2004-08-23
NO328546B1 (no) 2010-03-15
CZ20023963A3 (cs) 2003-03-12
TWI283662B (en) 2007-07-11
EP1299354B1 (en) 2009-07-22
JP4809570B2 (ja) 2011-11-09
CN1427818A (zh) 2003-07-02
DE60139320D1 (de) 2009-09-03
NZ522960A (en) 2004-05-28
ES2330412T3 (es) 2009-12-10

Similar Documents

Publication Publication Date Title
BR0111264A (pt) Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
DK1423357T3 (da) Urinstofderivater med antiproteolytisk aktivitet
PE20050156A1 (es) DERIVADOS DE INDOL COMO INHIBIDORES DEL FACTOR Xa
ATE429432T1 (de) Indazolderivate als faktor xa-inhibitoren
BR0011461A (pt) Inibidores do fator viia
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
BR0012610A (pt) Novo derivado de difenilpiperidina
TR199801229T2 (xx) ''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
BRPI0410446A (pt) derivados de benzimidazol como inibidores de fator xa
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm
HUP9900796A2 (hu) Szubsztituált pirrolok karbamidszármazékainak alkalmazása sclerosis multiplex kezelésére alkalmas gyógyszerkészítmények előállítására
US2491489A (en) Therapeutic composition of sulfonamides
IT1277736B1 (it) Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
JPS61277614A (ja) 抗プラスミン剤

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time